TY - JOUR
T1 - Dexamethasone to prevent kidney scarring in acute pyelonephritis :
T2 - a randomized clinical trial
AU - Rius-Gordillo, N.
AU - Ferré i Suana, Núria
AU - González-Rodríguez, Juan David
AU - Ibars, Zaira
AU - Parada, Ester
AU - Fraga Rodriguez, Gloria Maria
AU - Chocron, Sara
AU - Samper, Manuel
AU - Vicente, Carmen
AU - Fuertes, Jordi
AU - Escribano, Joaquín
PY - 2022
Y1 - 2022
N2 - Urinary tract infection (UTI) is one of the most common bacterial infections in childhood and is associated with long-term complications. We aimed to assess the effect of adjuvant dexamethasone treatment on reducing kidney scarring after acute pyelonephritis (APN) in children. Multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial (RCT) where children from 1 month to 14 years of age with proven APN were randomly assigned to receive a 3-day course of either an intravenous corticosteroid (dexamethasone 0.30 mg per kg/day) twice daily or placebo. The late technetium 99 m-dimercaptosuric acid scintigraphy (.
AB - Urinary tract infection (UTI) is one of the most common bacterial infections in childhood and is associated with long-term complications. We aimed to assess the effect of adjuvant dexamethasone treatment on reducing kidney scarring after acute pyelonephritis (APN) in children. Multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial (RCT) where children from 1 month to 14 years of age with proven APN were randomly assigned to receive a 3-day course of either an intravenous corticosteroid (dexamethasone 0.30 mg per kg/day) twice daily or placebo. The late technetium 99 m-dimercaptosuric acid scintigraphy (.
KW - Acute pyelonephritis
KW - Children
KW - Corticosteroids
KW - Kidney scar
U2 - 10.1007/s00467-021-05398-w
DO - 10.1007/s00467-021-05398-w
M3 - Article
C2 - 35041042
SN - 0931-041X
VL - 37
SP - 2109
EP - 2118
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 9
ER -